S. J. Wong

A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

J. Dancey, E. Vokes, E. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

D. Hayes, H. Lenz, E. Vokes, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.

M. Rupji, S. Koyfman, J. Geiger, 2024, JAMA oncology.

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

E. Vokes, E. Cohen, A. Mauer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.